Twitter | Search | |
Anthony Mato
Director, CLL program, MSKCC
1,274
Tweets
1,744
Following
2,128
Followers
Tweets
Anthony Mato May 30
Replying to @DrAnasYounes
Completely agree. Looking for an early win
Reply Retweet Like
Anthony Mato retweeted
Anthony Perissinotti May 30
1. No OS benefit with combo 2. “OS confounded in AZA only arm by subsequent ENA"... that is what's supposed to happen. Tells you whether combo is truly better vs just doing sequential. Why keep a patient on 2 therapies for ~2 years instead of 1 therapy at a time ($$$$?)?
Reply Retweet Like
Anthony Mato retweeted
Lymphoma Hub May 30
CONGRESS | | MURANO phase III trial | , of , reports a new analysis about the impact on survival outcomes of venetoclax early discontinuation, interruption, or dose modification when combined with rituximab to treat patients with R/R
Reply Retweet Like
Anthony Mato May 28
Good morning NYC
Reply Retweet Like
Anthony Mato May 27
Good morning NYC
Reply Retweet Like
Anthony Mato May 25
Replying to @SamanthaLWilson
Decline
Reply Retweet Like
Anthony Mato retweeted
Toby Eyre May 23
A really useful tool when widespread testing of IGHV status is performed. A predictive tool for early-stage CLL | Blood | American Society of Hematology
Reply Retweet Like
Anthony Mato May 24
Great question - we need randomized studies with VEN - G as control. CLL 17 will help answer the key questions
Reply Retweet Like
Anthony Mato May 24
A great moment in NYC history
Reply Retweet Like
Anthony Mato May 24
Replying to @ldparisi22 @jdsoumerai
is study lead. Defer questions to him
Reply Retweet Like
Anthony Mato retweeted
Toby Eyre May 24
Analysis of outcomes according to discontinuation reason in MURANO - Short term interruption not a/w ⬇️PFS - Early discontinuation clearly a/w ⬇️ PFS Optimum time length of therapy remains somewhat unclear in R/R . with and colleagues
Reply Retweet Like
Anthony Mato May 24
It’s next on list for analysis!
Reply Retweet Like
Anthony Mato May 24
Replying to @jdsoumerai
Reply Retweet Like
Anthony Mato May 24
"In this sad world of ours, sorrow comes to all; and, to the young, it comes with bitterest agony, because it takes them unawares. The older have learned to ever expect it. I am anxious to afford some alleviation of your present distress." - A Lincoln
Reply Retweet Like
Anthony Mato May 24
Data on BOVen regimen in frontline . High rates of undetectable MRD leading to time limited therapy. Great partnership between ⁦⁩ and ⁦
Reply Retweet Like
Anthony Mato May 24
⁩ presenting data on alternative CD20 use vs desensitization in lymphomas. An important practical comparison ⁦
Reply Retweet Like
Anthony Mato May 24
Presenting data on premature venetoclax discontinuation from Murano dataset ⁦⁩ (interruptions, dose reductions, early stopping effects on PFS and OS) ⁦
Reply Retweet Like
Anthony Mato May 21
Great discussion tonight with ⁦⁩ and ⁦⁩ moderated by ⁦⁩ on
Reply Retweet Like
Anthony Mato retweeted
Matthew Davids, MD May 21
Excited to be going “on air” in about 1 hour with and with : Understanding the Impact of COVID-19 on the Care of Patients with Chronic Lymphocytic Leukemia | Research To Practice
Reply Retweet Like
Anthony Mato May 21
Thanks for mentioning Andy and great work on his part! Andy you need a twitter handle!!!!
Reply Retweet Like